HC Wainwright Increases Monopar Therapeutics (NASDAQ:MNPR) Price Target to $22.00

Monopar Therapeutics (NASDAQ:MNPR) had its target price lifted by research analysts at HC Wainwright from $6.00 to $22.00 in a note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 27.54% from the stock’s previous close.

Separately, Rodman & Renshaw assumed coverage on Monopar Therapeutics in a research note on Friday, October 11th. They set a “buy” rating and a $50.00 target price for the company.

Monopar Therapeutics Stock Performance

Shares of MNPR opened at $17.25 on Monday. The stock has a market capitalization of $68.31 million, a PE ratio of -8.46 and a beta of 1.09. The company’s 50-day simple moving average is $7.84 and its 200-day simple moving average is $4.91. Monopar Therapeutics has a 1 year low of $1.37 and a 1 year high of $38.50.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings results on Friday, November 8th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.09. On average, sell-side analysts predict that Monopar Therapeutics will post -1.93 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Karthik Radhakrishnan acquired 1,550 shares of the firm’s stock in a transaction dated Monday, October 28th. The stock was acquired at an average cost of $16.25 per share, with a total value of $25,187.50. Following the transaction, the chief financial officer now owns 1,550 shares in the company, valued at approximately $25,187.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 34.90% of the stock is currently owned by company insiders.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.